CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to identify and validate biomarkers for the Insulin-like Growth Factor I Receptor in cancer, which is crucial for developing targeted therapies. The research combines expertise in IGF-I signaling and pharmacogenomics to enhance patient selection and treatment monitoring.
The Insulin-like Growth Factor I Receptor (IGF-IR) is widely expressed on human tissues and has been shown to promote the growth and invasiveness of cancer cells.
It is a potentially important therapeutic target for several major cancers including breast, lung and colon, and has attracted major interest from pharmaceutical companies and clinicians.
Currently, at least 70 clinical trials are underway to test several different IGF-IR kinase inhibitors and blocking antibodies.
However, unlike some…
UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, CRAIGAVON
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
